To address these issues, several therapeutic agents initially designed to target metabolic syndrome abnormalities, including statins, metformin, glucagon-like peptide 1 (GLP-1) agonists, ACE inhibitors (ACEi), ARBs, and sodium-glucose co-transporter 2 (SGLT2) inhibitors, have been integrated into clinical treatments. The gene discussed is GCG; the disease is metabolic syndrome.